Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 20, 2019 - Issue 9
Submit an article Journal homepage
1,607
Views
2
CrossRef citations to date
0
Altmetric
Editorial

Is there hope for spinal muscular atrophy synthetic pharmacotherapy?

Markus RiesslandLaboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-2592-5045View further author information
ORCID Icon
Pages 1049-1052 | Received 31 Jan 2019, Accepted 12 Mar 2019, Published online: 20 Mar 2019

References

  • Feldkotter M, Schwarzer V, Wirth R, et al. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002 Feb;70(2):358–368.
  • Munsat TL, Davies KE. International SMA consortium meeting (26–28 June 1992, Bonn, Germany). Neuromuscul Disord. 1992;2(5–6):423–428.
  • Rudnik-Schoneborn S, Berg C, Zerres K, et al. Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling. Clin Genet. 2009 Aug;76(2):168–178.
  • Zerres K, Rudnik-Schoneborn S, Forkert R, et al. Genetic basis of adult-onset spinal muscular atrophy. Lancet. 1995 Oct 28;346(8983):1162.
  • Wirth B, Garbes L, Riessland M. How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches. Curr Opin Genet Dev. 2013 Jun;23(3):330–338.
  • Lorson CL, Hahnen E, Androphy EJ, et al. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA. 1999 May 25;96(11):6307–6311.
  • Kashima T, Manley JL. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet. 2003 Aug;34(4):460–463.
  • Lim SR, Hertel KJ. Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3ʹ splice site pairing. J Biol Chem. 2001 Nov 30;276(48):45476–45483.
  • Kaczmarek A, Schneider S, Wirth B, et al. Investigational therapies for the treatment of spinal muscular atrophy. Expert Opin Investig Drugs. 2015;24(7):867–881.
  • Garbes L, Riessland M, Wirth B. Histone acetylation as a potential therapeutic target in motor neuron degenerative diseases. Curr Pharm Des. 2013;19(28):5093–5104.
  • Riessland M, Ackermann B, Forster A, et al. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum Mol Genet. 2010 Apr 15;19(8):1492–1506.
  • Kissel JT, Elsheikh B, King WM, Freimer M, Scott CB, Kolb SJ, et al. SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle Nerve. 2014 Feb;49(2):187–192.
  • Ratni H, Ebeling M, Baird J, et al. Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018 Aug 9;61(15):6501–6517.
  • Roche PR Roche announces new data for risdiplam in spinal muscular atrophy (SMA) at the world muscle society congress. Media Release. [cited 2019 Jan 28]. Available from: https://www.roche.com/media/releases/med-cor-2018-10-03.htm. 2018.
  • Singh NN, Howell MD, Androphy EJ, et al. How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy. Gene Ther. 2017 Sep;24(9):520–526.
  • Singh NK, Singh NN, Androphy EJ, et al. Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol. 2006 Feb;26(4):1333–1346.
  • Hua Y, Sahashi K, Rigo F, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature. 2011 Oct 5;478(7367):123–126.
  • Biogen. Biogen later-onset study results. [cited 2019 Mar 03]. Available from: https://wwwspinrazacom/en_us/home/results/later-onsethtml. 2019.
  • Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017 Nov 2;377(18):1723–1732.
  • Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018 Feb 15;378:(7)625–635.
  • Gidaro T, Servais L. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Dev Med Child Neurol. 2019 Jan;61(1):19–24.
  • Hwu W, De D, Bertini E, et al. Outcomes after 1-year in presymptomatic infants with genetically diagnosed spinal muscular atrophy (SMA) treated with nusinersen: interim results from the NURTURE study. Neuromuscul Disord. 2017;27:212.
  • Garcia-Lopez A, Tessaro F, Jonker HRA, et al. Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes. Nat Commun. 2018 May 23;9(1):2032.
  • Oprea GE, Krober S, McWhorter ML, et al. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science. 2008 Apr 25;320(5875):524–527.
  • Riessland M, Kaczmarek A, Schneider S, et al. Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis. Am J Hum Genet. 2017 Feb 02;100(2):297–315.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.